Comment le bénéfice par action récent de 01244.HK se compare-t-il aux attentes ?
Comment les revenus de 3D Medicines Inc. 01244.HK se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour 3D Medicines Inc. ?
Quel est le score de qualité des bénéfices pour 3D Medicines Inc. ?
Quand 3D Medicines Inc. publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de 3D Medicines Inc. ?
3D Medicines Inc. a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
--
Prix d'ouverture
--
Plage de la journée
-
Plage de 52 semaines
-
Volume
--
Volume moyen
360.0K
BPA (TTM)
-0.76
Rendement en dividend
--
Capitalisation boursière
--
Qu’est-ce que 3D MEDICINES ?
3D Medicines, Inc. is an investment holding company, which engages in biopharmaceutical research and development. The company is headquartered in Qingdao, Shandong and currently employs 183 full-time employees. The company went IPO on 2022-12-15. The firm focuses on the discovery, development and commercialization of innovative drugs in the field of cancer chronic disease treatment, and also lays out the field of cancer pain management. The firm has built a complete set of internal R&D systems, and has covered the entire process from drug discovery, preclinical development, clinical trials, and registration. The firm's first marketed drug, Envafolimab, is a subcutaneously injected PD-L1 inhibitor for the treatment of pan-tumor types. The firm also has a number of innovative drug research and development pipelines. The firm primarily operates in the domestic Chinese market.